Bio-Rad Laboratories, Inc. (BIO) has announced plans to launch new
Digital PCR Systems by 2025, which signals expansion and innovation in their product line. While Q2 Earnings are expected to decline, the company's
stock analysis shows rapid market gains, and potential for price growth in foreseeable future. The company suffered a setback with
stock prices dropping and investor's lost some confidence. Bio-Rad has made notable headlines with its low debt and recently expanded its
digital PCR portfolio with four new platforms. Meanwhile, the acquisition of
Stilla Technologies is seen as a strategic move that could reshape the market. Despite downward revision of price targets by analysts, the company enjoys attention from institutions due to its
outstanding yields. However, Bio-Rad's shares have slid and there could be weak spots in the company’s performance considering the 5% drop in the stock price this week. The
revenue declines were reportedly driven by a weak academic research market, resulting in lowered guidance. Nonetheless, Bio-Rad's stake in
Sartorius continues to drive the long-term value.
Bio-Rad Laboratories Stocks News Analytics from Tue, 30 Jun 2020 07:00:00 GMT to Sat, 26 Jul 2025 16:06:04 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -3
